AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Q32 Bio Sells Complement Inhibitor ADX-097 to Akebia Therapeutics for Upfront and Milestone Payments.
ByAinvest
Tuesday, Dec 2, 2025 3:48 am ET1min read
Q32 Bio has sold its complement inhibitor ADX-097 to Akebia Therapeutics, securing upfront and milestone payments that extend its cash runway into 2027. The deal includes $12 million in upfront and near-term milestone payments, potential development, regulatory, and commercial milestones totaling up to $592 million, and tiered royalties ranging from low single-digit to mid-teen percentages on future sales. Q32 Bio will focus on advancing its flagship program, bempikibart, for alopecia areata.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet